Friday, July 26, 2024
7/26/2024
ABSTRACT The recent development of T cell-based cancer immunotherapies, including checkpoint blockade (anti-PD-1, anti-CTLA-4 and others) or adoptive T cell therapy (ACT) using modified patient T cells, has led to improved patient outcomes for a variety of cancers. However, durable responses are observed in only a fraction of patients. Further progress can be made by studying and targeting different T cell signaling pathways, such as the T cell receptor (TCR)-CD3 signaling pathway. T cell recognition of antigen by the TCR and the resulting proximal signaling through surrounding CD3 subunits are key steps in the initiation of tumor-killing. Previous studies that targeted the antigen binding site of the TCR for enhancing T cell responses to tumor antigens often lead to off- target effects and toxicity. Instead, identification of the specific extracellular interactions between the TCR and CD3 subunits could offer precise guidance for the development of immunotherapeutic strategies that modulate T cell immunity by targeting signaling through the TCR-CD3 complex without altering antigen-specificity. Our preliminary data showed that mutating residues in the constant domain of the TCR resulted in altered T cell cytokine responses. Based on our preliminary data, our hypothesis is that by modulating TCR-CD3 signaling, immune-mediated cytotoxicity to tumor antigens can be enhanced without losing specificity for the cancer antigen. To test our hypothesis, in Aim 1 we will use an in vitro retroviral TCR display method, a novel CD3- tetramer assay, and an in-silico structure-based TCR design approach to identify signal-enhancing TCR mutants that enable T cells to mediate more effective in vitro tumor killing. In Aim 2, we will identify the mechanisms that drive altered signaling evidenced in select TCR signal-enhancing and signal-hampering mutants. In Aim 3, identified mutations will be introduced into gp100-specific TCRs with different antigen affinities and their in vitro and in vivo tumor killing efficacy will be analyzed to characterize the tumor killing potential, T cell differentiation, and T cell exhaustion patterns of new signal-enhancing T cell clones with the goal of developing a new strategy for effective T cell therapies against cancer.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
